ethyl 3,4,8-trimethyl-2-(phenylmethyl)-2-azabicyclo[2.2.2]octane-6-carboxylate

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 哌啶类
• 英文名称: ethyl 3,4,8-trimethyl-2-(phenylmethyl)-2-azabicyclo[2.2.2]octane-6-carboxylate
• 英文别名: ethyl 2-benzyl-3,4,8-trimethyl-2-azabicyclo[2.2.2]octane-6-carboxylate
• 化学式: C₂₀H₂₉NO₂
• 分子量: 315.456
• InChiKey: FITCSFPRZYVKMT-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.2
• 重原子数：
  23
• 可旋转键数：
  5
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.65
• 拓扑面积：
  29.5
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  ethyl 3,4,8-trimethyl-2-(phenylmethyl)-2-azabicyclo[2.2.2]octane-6-carboxylate 、 氯甲酸乙酯 、 甲烷 在 正丁基锂 、 二异丙胺 作用下， 以 四氢呋喃 、 正己烷 为溶剂， 以32.1 g (97%)的产率得到diethyl 3,4,8-trimethyl-2-(phenylmethyl)-2-azabicyclo-[2.2.2] octane-6,6-dicarboxylate
  参考文献：
  名称：

  Substituted 3-piperidinealkanoates and alkanones and compositions and

  摘要：

  该发明涉及一种化合物，用于治疗精神病，其化学式为：##STR1## 其中：R.sup.1为氢、较低烷基、苯基较低烷基、C.sub.3 -C.sub.7 单环环烷基较低烷基，或羟基-C.sub.3 -C.sub.7 单环环烷基较低烷基；R.sup.2为较低烷基；R.sup.3为氢或较低烷基；R.sup.4为较低烷基；n为从零到三的整数；R.sup.5为羟基、较低烷氧基、较低烷基、C.sub.3 -C.sub.7 单环环烷基、苯基，或从呋喃基、噻吩基和异噁唑基中选择的5-成员杂环；但当n为零时，R.sup.5不是羟基或其药用可接受的酸盐。

  公开号：

  US05286733A1

文献信息

• Substituted 3-piperidinealkanamines and alkanamides and compositions and
  申请人：Sterling Winthrop Inc.

  公开号：US05290796A1

  公开（公告）日：1994-03-01

  The invention is related to compounds, being useful in treating psychosis, of the formula: ##STR1## wherein R.sup.1 is lower-alkyl, or phenyl-lower-alkyl; R.sup.2, R.sup.3 and R.sup.4 are the same or different lower-alkyl; n is zero or one; R.sup.5 is hydrogen, lower-alkyl, C.sub.3 -C.sub.7 -monocyclic cycloalkyl, lower-alkoxy, phenyl, phenyl-lower-alkyl, phenyl-lower-alkyl in which the phenyl ring is substituted in the 2, 3, or 4-position by one to two, the same or different, halogen substituents, or R.sup.5 is a 5-membered aromatic monocyclic heterocycle selected from the group consisting of thienyl, furanyl and isoxazolyl; R.sup.6 is hydrogen or lower-alkyl; or when n is zero, R.sup.5 and R.sup.6 together are --(CH.sub.2).sub.m -- wherein m is an integer from four to six; with the proviso that when R.sup.1, R.sup.2, R.sup.3 and R.sup.4 are methyl, n is zero and R.sup.6 is hydrogen or methyl, R.sup.5 cannot be hydrogen; further provided that when n is zero, R.sup.5 cannot be lower-alkoxy, phenyl, or a 5-membered aromatic monocyclic heterocycle, or a pharmaceutically acceptable acid-addition salt thereof.

  这项发明涉及一种化合物，用于治疗精神病，其化学式为：##STR1## 其中R.sup.1是较低烷基，或苯基较低烷基；R.sup.2、R.sup.3和R.sup.4是相同或不同的较低烷基；n为零或一；R.sup.5是氢、较低烷基、C.sub.3 -C.sub.7-单环脂肪环烷基、较低烷氧基、苯基、苯基较低烷基、苯基较低烷基，其中苯环在2、3或4位被一个或两个相同或不同的卤素取代，或者R.sup.5是从噻吩基、呋喃基和异噁唑基中选择的5-成员芳香单环杂环；R.sup.6是氢或较低烷基；或者当n为零时，R.sup.5和R.sup.6一起是--(CH.sub.2).sub.m--，其中m是从四到六的整数；但是当R.sup.1、R.sup.2、R.sup.3和R.sup.4为甲基，n为零且R.sup.6为氢或甲基时，R.sup.5不能是氢；进一步规定当n为零时，R.sup.5不能是较低烷氧基、苯基或5-成员芳香单环杂环，或其药用可接受的酸盐。
• Substituted 2-azabicyclo[2.2.2]octane derivatives and compositions and
  申请人：Sterling Winthrop Inc.

  公开号：US05240935A1

  公开（公告）日：1993-08-31

  Novel substituted 2-azabicyclo[2.2.2]octane derivatives, pharmaceutical compositions containing them, methods for treating central nervous system disorders utilizing them, and processes for synthesizing them.

  新型替代的2-azabicyclo[2.2.2]辛烷衍生物，含有它们的药物组合物，利用它们治疗中枢神经系统疾病的方法，以及合成它们的过程。
• Sigma ligands for use in the prevention and/or treatment of postoperative pain
  申请人：Laboratorios del. Dr. Esteve, S.A.

  公开号：EP2353598A1

  公开（公告）日：2011-08-10

  The invention refers to the use of a sigma ligand, particularly a sigma ligand of formulae (I), (II) or (III) to prevent and/or treat acute and chronic pain developed as a consequence of surgery, especially superficial and/or deep pain secondary to surgical tissue injury, and peripheral neuropathic pain, neuralgia, allodynia, causalgia, hyperalgesia, hyperesthesia, hyperpathia, neuritis or neuropathy secondary to surgical procedure.

  本发明涉及使用sigma配体，特别是公式（I），（II）或（III）的sigma配体，以预防和/或治疗由手术引起的急性和慢性疼痛，特别是手术组织损伤引起的表浅和/或深层疼痛，以及周围神经病理性疼痛，神经痛，触痛，烧伤性痛，痛觉过敏，疼痛过敏，神经炎或手术过程引起的神经病变。
• Penta and tetrasubstituted piperidines and compositions and method of
  申请人：Sterling Wintrop Inc.

  公开号：US05290789A1

  公开（公告）日：1994-03-01

  The invention is related to compounds, being useful in treating psychosis, of the formula: ##STR1## wherein: R.sup.1 is hydrogen, lower-alkyl or phenyl-lower-alkyl; R.sup.2 and R.sup.4 are the same or different lower-alkyl; R.sup.3 is hydrogen or lower-alkyl; m is two or three; n is an integer from zero to three; and R.sup.5 is hydrogen, lower-alkyl, C.sub.3 -C.sub.7 -monocyclic cycloalkyl, allyl, or propargyl; or a pharmaceutically acceptable acid-addition salt thereof.

  本发明涉及一种化合物，其公式如下，可用于治疗精神病：##STR1##其中：R.sup.1是氢、较低烷基或苯基较低烷基；R.sup.2和R.sup.4是相同或不同的较低烷基；R.sup.3是氢或较低烷基；m为2或3；n为0到3的整数；R.sup.5是氢、较低烷基、C.sub.3-C.sub.7-单环环烷基、烯丙基或丙炔基；或其药学上可接受的酸加盐。
• Sigma ligands for the prevention and/or treatment of emesis induced by chemotherapy or radiotherapy
  申请人：Laboratorios del. Dr. Esteve, S.A.

  公开号：EP2388005A1

  公开（公告）日：2011-11-23

  The invention refers to the use of a sigma ligand, preferably a sigma ligand of formula (I), to prevent or treat emesis induced by a chemotherapeutic agent or radioactivity, especially emesis induced by taxanes, vinca alkaloids or platin chemotherapeutic drugs.

  本发明是指使用σ配体，最好是式(I)的σ配体，来预防或治疗由化疗药物或放射性诱发的呕吐，特别是由紫杉类、长春花生物碱或铂类化疗药物诱发的呕吐。